Ibrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> Alterations.

ABSTRACT:

SUBMITTER: Ahn IE 

PROVIDER: S-EPMC7456330 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature